about
IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth.A novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathyBAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages.Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity.Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.Role of BAG3 in cancer progression: A therapeutic opportunity.Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer.Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis.BAG3 protein is induced during cardiomyoblast differentiation and modulates myogenin expression.BAG3 Protein Is Involved in Endothelial Cell Response to Phenethyl Isothiocyanate.Discovery and synthesis of the first selective BAG domain modulator of BAG3 as an attractive candidate for the development of a new class of chemotherapeuticsBAG3 protein in advanced-stage heart failureImmunohistochemistry for BAG3 in cervical precancerous lesionsCAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs-LetterBAG3 expression correlates with the grade of dysplasia in squamous intraepithelial lesions of the uterine cervixDevelopment of an anti-BAG3 humanized antibody for treatment of pancreatic cancerThe multiple activities of BAG3 protein: Mechanisms
P50
Q33842059-A3986B98-6901-4940-81A5-5438684122ADQ36246459-21CC3E90-249C-4439-A6CD-A7D5E1A70EDAQ36319886-285F4C37-CA79-48F3-B7A8-A57077523A8DQ38009588-6F1FBCF7-7051-474C-897D-3AF53038BD80Q39286125-1382D4C1-F208-427C-90DE-F3059B93FCEBQ46754787-5BAF176B-23EF-426F-89DA-5BDF7C1759F7Q47139368-D365F628-A42C-4697-859C-8E9F80494954Q47868438-FE3328E9-E565-4569-8705-F619A741B941Q48251095-039338AC-06A5-494B-AE9B-954781B4D3EEQ50307931-DE7460E9-A04F-4262-A24E-96ECEF2E6736Q53268924-463F3E65-2394-49FE-B050-EF800C598684Q55411962-50D8C56E-8CBA-4404-8596-D04EA6337082Q57177046-E88C4885-F081-471F-BEBD-4C1793B1B398Q85644112-9C82DECA-F3EA-45FE-92E8-1C652FF0F277Q90830522-F08FAB75-3480-4B56-85B7-700F7B29BA3FQ91061726-F41193EF-2142-4383-88EF-3F6935155FA7Q92836155-17326541-18EB-4053-A641-8AFB8D03D16EQ93024442-F9D24ABE-78B5-4DE4-B292-AF57EB4617C3Q94489933-66153BDB-E5ED-4E00-B656-EDE158E5750C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Margot De Marco
@ast
Margot De Marco
@en
Margot De Marco
@es
Margot De Marco
@nl
Margot De Marco
@sl
type
label
Margot De Marco
@ast
Margot De Marco
@en
Margot De Marco
@es
Margot De Marco
@nl
Margot De Marco
@sl
prefLabel
Margot De Marco
@ast
Margot De Marco
@en
Margot De Marco
@es
Margot De Marco
@nl
Margot De Marco
@sl
P106
P1153
36171597900
P31
P496
0000-0003-4134-1437